CC
Commodore Capital’s Celldex Therapeutics CLDX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $70.2M | Buy |
3,450,000
+250,000
| +8% | +$5.09M | 4.96% | 6 |
|
|
2025
Q1 | $58.1M | Buy |
+3,200,000
| New | +$58.1M | 4.28% | 10 |
|
|
2024
Q4 | – | Sell |
-1,618,937
| Closed | -$55M | – | 36 |
|
|
2024
Q3 | $55M | Buy |
1,618,937
+193,937
| +14% | +$6.59M | 3.44% | 12 |
|
|
2024
Q2 | $52.7M | Buy |
1,425,000
+558,532
| +64% | +$20.7M | 3.6% | 9 |
|
|
2024
Q1 | $36.4M | Buy |
866,468
+164,501
| +23% | +$6.9M | 2.43% | 14 |
|
|
2023
Q4 | $27.8M | Sell |
701,967
-4,698
| -0.7% | -$186K | 2.43% | 16 |
|
|
2023
Q3 | $19.4M | Buy |
706,665
+75,000
| +12% | +$2.06M | 2.27% | 16 |
|
|
2023
Q2 | $21.4M | Buy |
631,665
+135,842
| +27% | +$4.61M | 2.41% | 14 |
|
|
2023
Q1 | $17.8M | Hold |
495,823
| – | – | 2.72% | 13 |
|
|
2022
Q4 | $22.1M | Sell |
495,823
-42,989
| -8% | -$1.92M | 3.33% | 10 |
|
|
2022
Q3 | $15.1M | Hold |
538,812
| – | – | 2.44% | 14 |
|
|
2022
Q2 | $14.5M | Buy |
538,812
+297,613
| +123% | +$8.02M | 3.07% | 13 |
|
|
2022
Q1 | $8.22M | Buy |
+241,199
| New | +$8.22M | 1.83% | 18 |
|
|
2021
Q4 | – | Sell |
-248,207
| Closed | -$13.4M | – | 27 |
|
|
2021
Q3 | $13.4M | Sell |
248,207
-75,230
| -23% | -$4.06M | 3.53% | 13 |
|
|
2021
Q2 | $10.8M | Sell |
323,437
-46,514
| -13% | -$1.56M | 3.77% | 11 |
|
|
2021
Q1 | $7.62M | Buy |
369,951
+13,520
| +4% | +$279K | 3.04% | 15 |
|
|
2020
Q4 | $6.25M | Buy |
+356,431
| New | +$6.25M | 3.4% | 15 |
|